OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 675 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR What Do You Put In Your Pocket? April 28, 2021 FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera March 28, 2024 For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge January 8, 2020 Load more HOT NEWS Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC...
